Bay Street News, May 14th, 2024

CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that […]

Overall response rate of 70% observed in 10 evaluable heavily pretreated CLL patients Data showcase deepening clinical responses with longer […]

– Data from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia to be Presented in Plenary Session – – […]

Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-off date Updated data to […]

LONDON, May 14, 2024 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell […]

Tuesday, May 14, 2024 Dear Shareholders and Investors, Please be advised that our 1Q 2024 Earnings Report is scheduled for release […]

MONTREAL, May 14, 2024 (GLOBE NEWSWIRE) — Boralex Inc. (“Boralex” or the “Company”) (TSX: BLX) announces that it will hold […]

New products broaden Merit’s leadership in embolotherapy. Full portfolio will be exhibited at the 18thAnnual GEST Meeting May 16-19 in […]

$150 million capital infusion allows Mullen and Bollinger to operate and expand domestic and international commercial sales efforts These commitments […]

FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) — Celularity Inc. (NASDAQ: CELU) (“Celularity”), a regenerative and cellular medicine company developing […]